The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: Results of a randomized, double-blind, placebo-controlled MR-monitored phase II trial
Abstract
We report the results of a randomized, double-blind, placebo-controlled exploratory trial of the chimeric monoclonal anti-CD4 antibody cM-T412 in 71 patients suffering from active relapsing-remitting and secondary progressive multiple sclerosis. Infusion of the antibody produced frequent but usually minor side effects and resulted in a long-lasting reduction of circulating CD4-positive T cells. There was no significant effect on the primary measure of efficacy, the number of active lesions on monthly gadolinium-enhanced MRI over 9 months. Further statistical evaluation provided evidence that the degree of depletion of CD4-positive cells was important with regard to treatment efficacy; using CD4 counts as a covariate there was a statistically significant effect on the number of active lesions over 18 months (p = 0.04). There was a statistically significant reduction of 41% in the number of clinical relapses (a secondary efficacy parameter) after 9 months (p = 0.02), which was still present after 18 months, but this finding may be partly due to physician unblinding. Other secondary efficacy parameters (Expanded Disability Status Scale progression, number of courses of methylprednisolone) were not influenced by anti-CD4 treatment. We conclude that intravenous treatment with the monoclonal antibody cM-T412 in the dosage we used results in a substantial and sustained reduction of the number of circulating CD4-positive cells, but is not able to reduce MS activity as measured by monthly gadolinium-enhanced MRI, and is therefore unlikely to have a beneficial effect on the clinical disease course. We found preliminary evidence suggesting that more aggressive depletion of CD4-positive cells might lead to a more substantial reduction in MRI activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The pathophysiology of brain ischemia
Raichle, M. E. (1983) · Annals of Neurology · doi:10.1002/ana.410130103 · Cited by 634
Functional mapping of brain areas implicated in auditory—verbal memory function
Grasby, P. M., Frith, C. D., Friston, K. J., Bench, C., Frackowiak, R. S. J., & Dolan, R. J. (1993) · Brain · doi:10.1093/brain/116.1.1 · Cited by 560
Major differences in the dynamics of primary and secondary progressive multiple sclerosis
Thompson, A. J., Kermode, A. G., Wicks, D., MacManus, D. G., Kendall, B. E., Kingsley, D. P. E., & McDonald, W. I. (1991) · Annals of Neurology · doi:10.1002/ana.410290111 · Cited by 486
Self-citationMiller, D. H., Albert, P. S., Barkhof, F., Francis, G., Frank, J. A., Hodgkinson, S., Lublin, F. D., Paty, D. W., Reingold, S. C., & Simon, J. (1996) · Annals of Neurology · doi:10.1002/ana.410390104 · Cited by 444
Self-citationMultiple Sclerosis: Distribution of T Cell Subsets Within Active Chronic Lesions
Traugott, U., Reinherz, E. L., & Raine, C. S. (1983) · Science · doi:10.1126/science.6217550 · Cited by 421
Waldor, M. K., Sriram, S., Hardy, R., Herzenberg, L. A., Herzenberg, L. A., Lanier, L., Lim, M., & Steinman, L. (1985) · Science · doi:10.1126/science.3155574 · Cited by 322
Harris, J. O., Frank, J. A., Patronas, N., McFarlin, D. E., & McFarland, H. F. (1991) · Annals of Neurology · doi:10.1002/ana.410290515 · Cited by 303
Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis
Moreau, T., Coles, A., Wing, M., Isaacs, J., Hale, G., Waldmann, H., & Compston, A. (1996) · Brain · doi:10.1093/brain/119.1.225 · Cited by 250
Outcomes assessment in multiple sclerosis clinical trials: a critical analysis
Whitaker, J., McFarland, H., Rudge, P., & Reingold, S. (1995) · Multiple Sclerosis Journal · doi:10.1177/135245859500100107 · Cited by 236
Self-citationSerial gadolinium‐enhanced MRI in relapsing/remitting multiple sclerosis of varying disease duration
Thompson, A. J., Miller, D., Youl, B., MacManus, D., Moore, S., Kingsley, D., Kendall, B., Feinstein, A., & McDonald, W. I. (1992) · Neurology · doi:10.1212/wnl.42.1.60 · Cited by 220
Self-citation
Cited by
Treatment of Multiple Sclerosis: A Review
Hauser, S. L., & Cree, B. A. C. (2020) · The American Journal of Medicine · doi:10.1016/j.amjmed.2020.05.049 · Cited by 969
Multiple Sclerosis: Mechanisms and Immunotherapy
Baecher-Allan, C., Kaskow, B. J., & Weiner, H. L. (2018) · Neuron · doi:10.1016/j.neuron.2018.01.021 · Cited by 938
A Pathogenic Role for Myelin-Specific Cd8+ T Cells in a Model for Multiple Sclerosis
Huseby, E. S., Liggitt, D., Brabb, T., Schnabel, B., Öhlén, C., & Goverman, J. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.5.669 · Cited by 659
New concepts in the immunopathogenesis of multiple sclerosis
Hemmer, B., Archelos, J. J., & Hartung, H.-P. (2002) · Nature Reviews Neuroscience · doi:10.1038/nrn784 · Cited by 580
Multiple sclerosis: risk factors, prodromes, and potential causal pathways
Ramagopalan, S. V., Dobson, R., Meier, U. C., & Giovannoni, G. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70094-6 · Cited by 548
Metadata
- Authors
- van Oosten, B. W., Lai, M., Hodgkinson, S., Barkhof, F., Miller, D. H., Moseley, I. F., Thompson, A. J., Rudge, P., McDougall, A., McLeod, J. G., Adèr, H. J., & Polman, C. H.
- Venue
- Neurology
- Published
- 1997-08
- Volume
- 49
- Issue
- 2
- Pages
- 351-357
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2011854432
- Cited by
- 264
- References
- 16
- FWCI
- 5.94
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: Results of a randomized, double-blind, placebo-controlled MR-monitored phase II trial. https://app.cochat.ai/papers/10.1212/wnl.49.2.351
- The paper
- van Oosten, B. W., Lai, M., Hodgkinson, S., Barkhof, F., Miller, D. H., Moseley, I. F., Thompson, A. J., Rudge, P., McDougall, A., McLeod, J. G., Adèr, H. J., & Polman, C. H. (1997). Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: Results of a randomized, double-blind, placebo-controlled MR-monitored phase II trial. Neurology. https://doi.org/10.1212/wnl.49.2.351
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.